4D Molecular Therapeutics, Inc.

FDMT · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
100
SEC Filings

Business Summary

PART I Item 1. B usiness. Overv iew We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients. Our products are developed with customized and evolved adeno-associated virus (AAV) vectors invented from our proprietary vector discovery platform, Therapeutic Vector Evolution (TVE) which was designed to generate vectors with properties that overcome the limit...

Next Earnings

Q2 FY2026 — expected 2026-08-06

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionFDMTdiscussed_in_filing Cybersecurity
topic_mentionFDMTdiscussed_in_filing Cybersecurity
topic_mentionFDMTdiscussed_in_filing Healthcare & Bio
topic_mentionFDMTdiscussed_in_filing Platform & Ecosystem
topic_mentionFDMTdiscussed_in_filing Healthcare & Bio
topic_mentionFDMTdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-182025-12-310001193125-26-114075EDGAR98K words
2025-02-282024-12-310000950170-25-030056EDGAR—
2024-02-292023-12-310000950170-24-023183EDGAR—
2023-03-152022-12-310000950170-23-008142EDGAR—
2022-03-282021-12-310000950170-22-004794EDGAR—
2021-03-252020-12-310001564590-21-015502EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001193125-25-273343EDGAR72K words
2025-08-112025-06-300000950170-25-106244EDGAR—
2025-05-082025-03-310000950170-25-067040EDGAR—
2024-11-132024-09-300000950170-24-126370EDGAR—
2024-08-082024-06-300000950170-24-094010EDGAR—
2024-05-092024-03-310000950170-24-056933EDGAR—
2023-11-092023-09-300000950170-23-062103EDGAR—
2023-08-092023-06-300000950170-23-040661EDGAR—
2023-05-112023-03-310000950170-23-020703EDGAR—
2022-11-082022-09-300000950170-22-023185EDGAR—
2022-08-112022-06-300000950170-22-016882EDGAR—
2022-05-122022-03-310000950170-22-009702EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-300001193125-26-131739EDGAR1K words
2026-03-180001193125-26-113949EDGAR—
2026-01-260001193125-26-022559EDGAR—
2026-01-070001193125-26-005470EDGAR—
2025-12-100001193125-25-314167EDGAR—
2025-11-170001193125-25-283861EDGAR—
2025-11-100001193125-25-273340EDGAR—
2025-11-070001193125-25-272286EDGAR—
2025-11-060001193125-25-267934EDGAR—
2025-10-310001193125-25-259302EDGAR—

100 total filings indexed. 72 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc. ABOS — Acumen Pharmaceuticals, Inc.

Company Identity

CIK0001650648
TickerFDMT
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: afcb61b021ad70942d07ab04210b784d4940541dd359d70923c975b09a12dd98
parent: a43bb0c804752f8aea7bc6c245f034383fd07db52a8114b820f1a03002336925
content hash: 6eb281524fd24d4eea4e4fd241623fd1e261b6c0ab11614a95a9f62ad22f3479
signed: 2026-04-13T04:45:01.057Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf